Skip to main content
Premium Trial:

Request an Annual Quote

Luminex Closes Tm Bioscience Acquisition

NEW YORK (GenomeWeb News) — Luminex today said it has closed its acquisition of Tm Bioscience after receiving the green light from a Canadian court on Wednesday.
 
Under the terms of the deal, disclosed last December, Luminex will acquire all of the outstanding shares of Tm. Tm shareholders will receive .6 shares of Luminex common stock for each Tm share, leaving Tm holders with roughly 9 percent of Luminex’s stock.
 
Luminex CEO and President Patrick Balthrop said the company plans to market Tm’s molecular detection chemistries, assay kits, and reagents through its distribution partners.